PAHC Valuation

Phibro Animal Health Corp

Add to Watchlist

Advanced Chart

45.170

+0.47(1.051%)1D

PAHC Relative Valuation

PAHC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PAHC is overvalued; if below, it's undervalued.

Historical Valuation

Phibro Animal Health Corp (PAHC) is now in the Fair zone, suggesting that its current forward PE ratio of 16.15 is considered Fairly compared with the five-year average of 13.71. The fair price of Phibro Animal Health Corp (PAHC) is between 40.37 to 54.58 according to relative valuation methord.

Relative Value

Fair Zone

40.37-54.58

Current Price：45.17

Fair

16.15

Trailing

Forward

10.73

EV/EBITDA

Phibro Animal Health Corp. (PAHC) has a current EV/EBITDA of 10.73. The 5-year average EV/EBITDA is 9.14. The thresholds are as follows: Strongly Undervalued below 5.86, Undervalued between 5.86 and 7.50, Fairly Valued between 10.78 and 7.50, Overvalued between 10.78 and 12.42, and Strongly Overvalued above 12.42. The current Forward EV/EBITDA of 10.73 falls within the Historic Trend Line -Fairly Valued range.

12.87

EV/EBIT

Phibro Animal Health Corp. (PAHC) has a current EV/EBIT of 12.87. The 5-year average EV/EBIT is 12.33. The thresholds are as follows: Strongly Undervalued below 8.72, Undervalued between 8.72 and 10.53, Fairly Valued between 14.14 and 10.53, Overvalued between 14.14 and 15.95, and Strongly Overvalued above 15.95. The current Forward EV/EBIT of 12.87 falls within the Historic Trend Line -Fairly Valued range.

45.32

Phibro Animal Health Corp. (PAHC) has a current PS of 45.32. The 5-year average PS is 1.17. The thresholds are as follows: Strongly Undervalued below -7.14, Undervalued between -7.14 and -2.98, Fairly Valued between 5.33 and -2.98, Overvalued between 5.33 and 9.49, and Strongly Overvalued above 9.49. The current Forward PS of 45.32 falls within the Strongly Overvalued range.

12.42

P/OCF

Phibro Animal Health Corp. (PAHC) has a current P/OCF of 12.42. The 5-year average P/OCF is 4.33. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -0.35, Fairly Valued between 9.01 and -0.35, Overvalued between 9.01 and 13.69, and Strongly Overvalued above 13.69. The current Forward P/OCF of 12.42 falls within the Overvalued range.

25.17

P/FCF

Phibro Animal Health Corp. (PAHC) has a current P/FCF of 25.17. The 5-year average P/FCF is 8.68. The thresholds are as follows: Strongly Undervalued below -6.91, Undervalued between -6.91 and 0.89, Fairly Valued between 16.47 and 0.89, Overvalued between 16.47 and 24.26, and Strongly Overvalued above 24.26. The current Forward P/FCF of 25.17 falls within the Strongly Overvalued range.

Phibro Animal Health Corp (PAHC) has a current Price-to-Book (P/B) ratio of 5.89. Compared to its 3-year average P/B ratio of 2.87 , the current P/B ratio is approximately 105.71% higher. Relative to its 5-year average P/B ratio of 3.18, the current P/B ratio is about 85.35% higher. Phibro Animal Health Corp (PAHC) has a Forward Free Cash Flow (FCF) yield of approximately 0.02%. Compared to its 3-year average FCF yield of 0.53%, the current FCF yield is approximately -96.46% lower. Relative to its 5-year average FCF yield of 0.75% , the current FCF yield is about -97.52% lower.

5.89

P/B

Median3y

2.87

Median5y

3.18

0.02

FCF Yield

Median3y

0.53

Median5y

0.75

Competitors Valuation Multiple

The average P/S ratio for PAHC's competitors is 23.16, providing a benchmark for relative valuation. Phibro Animal Health Corp Corp (PAHC) exhibits a P/S ratio of 45.32, which is 95.65% above the industry average. Given its robust revenue growth of 39.73%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PAHC.O

Phibro Animal Health Corp

Spyre Therapeutics Inc

23.43

1.76B

HRMY.O

Harmony Biosciences Holdings Inc

Performance Decomposition

Market capitalization of PAHC increased by 92.23% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 2.68 to 7.29.

The secondary factor is the Revenue Growth, contributed 39.73%to the performance.

Overall, the performance of PAHC in the past 1 year is driven by Margin Expansion. Which is more sustainable.

39.73%

260.43M → 363.89M

Revenue Growth

172.01%

2.68 → 7.29

Margin Expansion

-119.51%

-139.05 → 27.13

P/E Change

92.23%